This document summarizes analysis of unpartnered pharmaceutical products from Medtrack in September 2015. It finds that opportunities remain abundant, with many preclinical and early-stage candidates in private company pipelines as well as late-stage candidates in public company pipelines. Oncology remains the leading therapeutic area for unpartnered drugs. Several private and public companies are highlighted that have significant unpartnered pipelines that could be candidates for partnership or acquisition deals. The document analyzes Phase III candidates in more detail and finds some oncology drugs that have above average likelihood of approval based on proprietary modeling.
This document analyzes and dispels five common myths about the drug delivery industry. It argues that drug delivery has delivered many new products, the market is growing not declining, the business model can be sustainable, product line extensions using drug delivery approaches are effective strategies, and drug delivery companies offer diverse technologies, not just similar controlled release solutions. The drug delivery industry plays a key role in addressing challenges in pharma by developing improved treatment options.
The contract research organization (CRO) industry is a multi-billion dollar industry that is expected to grow substantially over the next five years. There are over 1,000 CROs globally, ranging in size from small firms to large publicly traded companies. The top five CROs capture over a third of total industry revenue, suggesting market consolidation. Growth in the industry is driven by increasing complexity and size of clinical trials, globalization of drug development, and pharmaceutical industry cost containment pressures that encourage further outsourcing of services.
The document analyzes Merck and Sanofi against key success factors in the pharmaceutical industry. It identifies the three main success factors as strategic mergers and acquisitions, capitalizing on growth opportunities in areas like diabetes and oncology, and navigating the patent process. After evaluating the companies on these factors, the analysis concludes that Merck is currently in a more favorable position compared to Sanofi.
The document discusses emerging business and operational models in the pharmaceutical industry. It notes that the traditional vertically integrated model is shifting to a more fragmented model. It also discusses factors driving changes like rising costs and competition. The document analyzes current blockbuster and niche models and potential future models involving more specialization. It proposes a "progressive drug development model" to reduce risks and costs through targeted development.
Momenta Pharmaceuticals is a biotechnology company focused on developing generic versions of complex drugs and biosimilars. It has one approved product, a generic version of Lovenox, and received approval for a generic version of Copaxone in 2015. The company partners with larger drug manufacturers for commercialization who obtain marketing approval. Momenta earns revenue through profit sharing, royalties, licensing fees, and research services. It has a pipeline of 10 drug candidates and sees its partnership with MIT and proprietary sequencing technology as competitive advantages. Historically the company has experienced fluctuating revenues and losses as it funds research and development but maintains liquidity through investments in market securities.
This document analyzes Merck Pvt. Ltd. using Porter's Five Forces framework. It finds that competitive rivalry in the pharmaceutical industry is high due to many competitors. However, supplier power is low because suppliers are numerous and switching costs are low. Buyer power varies from low to moderate depending on the type of buyer. The threat of substitution is moderate to low, except for expired patents where generics pose a high threat. Barriers to entry are high due to regulatory hurdles and R&D costs.
Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional P...ReportsnReports
This 220-page report from Kalorama Information analyzes the pharmaceutical pipelines of the top 50 pharmaceutical companies to provide estimates and forecasts of the biopharmaceutical market through 2016. The report covers each company's financial performance, research and development spending, and late-stage drug pipeline. It also examines key issues and trends in the industry, such as biotechnology drug development, mergers and acquisitions, and the growing role of biopharmaceuticals.
“Managing the changing biopharma risk equation” is an Economist Intelligence Unit (EIU) report sponsored by MilliporeSigma. This paper explores in detail global pharmaceutical companies’ growth strategies and their plans for managing the associated risks.
This document analyzes and dispels five common myths about the drug delivery industry. It argues that drug delivery has delivered many new products, the market is growing not declining, the business model can be sustainable, product line extensions using drug delivery approaches are effective strategies, and drug delivery companies offer diverse technologies, not just similar controlled release solutions. The drug delivery industry plays a key role in addressing challenges in pharma by developing improved treatment options.
The contract research organization (CRO) industry is a multi-billion dollar industry that is expected to grow substantially over the next five years. There are over 1,000 CROs globally, ranging in size from small firms to large publicly traded companies. The top five CROs capture over a third of total industry revenue, suggesting market consolidation. Growth in the industry is driven by increasing complexity and size of clinical trials, globalization of drug development, and pharmaceutical industry cost containment pressures that encourage further outsourcing of services.
The document analyzes Merck and Sanofi against key success factors in the pharmaceutical industry. It identifies the three main success factors as strategic mergers and acquisitions, capitalizing on growth opportunities in areas like diabetes and oncology, and navigating the patent process. After evaluating the companies on these factors, the analysis concludes that Merck is currently in a more favorable position compared to Sanofi.
The document discusses emerging business and operational models in the pharmaceutical industry. It notes that the traditional vertically integrated model is shifting to a more fragmented model. It also discusses factors driving changes like rising costs and competition. The document analyzes current blockbuster and niche models and potential future models involving more specialization. It proposes a "progressive drug development model" to reduce risks and costs through targeted development.
Momenta Pharmaceuticals is a biotechnology company focused on developing generic versions of complex drugs and biosimilars. It has one approved product, a generic version of Lovenox, and received approval for a generic version of Copaxone in 2015. The company partners with larger drug manufacturers for commercialization who obtain marketing approval. Momenta earns revenue through profit sharing, royalties, licensing fees, and research services. It has a pipeline of 10 drug candidates and sees its partnership with MIT and proprietary sequencing technology as competitive advantages. Historically the company has experienced fluctuating revenues and losses as it funds research and development but maintains liquidity through investments in market securities.
This document analyzes Merck Pvt. Ltd. using Porter's Five Forces framework. It finds that competitive rivalry in the pharmaceutical industry is high due to many competitors. However, supplier power is low because suppliers are numerous and switching costs are low. Buyer power varies from low to moderate depending on the type of buyer. The threat of substitution is moderate to low, except for expired patents where generics pose a high threat. Barriers to entry are high due to regulatory hurdles and R&D costs.
Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional P...ReportsnReports
This 220-page report from Kalorama Information analyzes the pharmaceutical pipelines of the top 50 pharmaceutical companies to provide estimates and forecasts of the biopharmaceutical market through 2016. The report covers each company's financial performance, research and development spending, and late-stage drug pipeline. It also examines key issues and trends in the industry, such as biotechnology drug development, mergers and acquisitions, and the growing role of biopharmaceuticals.
“Managing the changing biopharma risk equation” is an Economist Intelligence Unit (EIU) report sponsored by MilliporeSigma. This paper explores in detail global pharmaceutical companies’ growth strategies and their plans for managing the associated risks.
Pharmaceutical Industry Environmental Analysis (Sanofi, Merck & Co.)Steven Sabo
The document is a letter of transmittal from a team of students to their professors submitting a report analyzing the global pharmaceutical companies Merck & Co. and Sanofi. The team's analysis identified three key success factors for companies in the industry and concluded that based on these factors, Sanofi is currently in a better position than Merck & Co. to succeed. The letter requests feedback from the professors and offers to further discuss the report and its analyses and recommendations.
The National Association of Pharmaceutical Manufacturers (NAPM) was established in 1977 as A Section 21 Trade Association which. It is a voluntary, non-profit organisation consisting of South African and Generics based Pharmaceutical manufacturers and distributors. The NAPM has a diverse membership comprising of 18 companies. Part of the NAPM’s function is to ensure that the sector plays a constructive role in our country’s economic growth, development and transformation and thereby create an environment in which the sector can thrive, expand, be competitive and enhance access of medicines to all of our country’s citizens.
Global Pharmaceutical Contract Manufacturing Resource Pack 2011Veronica Araujo
This document provides an overview of the global pharmaceutical contract manufacturing industry. It discusses key reasons why pharmaceutical companies outsource manufacturing, including lack of internal capacity, expertise, and the potential for cost savings. The most commonly outsourced areas of production are finished medicines. Emerging markets like India, China, and others offer lower costs and are attractive outsourcing destinations. However, outsourcing also presents challenges such as language/cultural barriers, meeting regulatory/quality requirements, and managing distant relationships. Overall, cost savings remain the top motivation for the 60% of pharmaceutical and biopharmaceutical manufacturing that is outsourced globally.
NAPM is a Section 21 Trade Association which was established in 1977. It is a voluntary, non-profit organisation consisting of South African and Generics based Pharmaceutical manufacturers and distributors. NAPM has a diverse membership comprising of 24 companies. Some of the NAPM’s function is to ensure that the sector plays a constructive role in our country’s economic growth, development and transformation and thereby create an environment in which the sector can thrive, expand, be competitive and enhance access of medicines to all of our country’s citizens.
What is the "Drugs (Prices Control) Order (DPCO)" ? The Drugs Prices Control Order, 1995 is an order issued by the Government of India under Sec. 3 of Essential Commodities Act, 1955 to regulate the prices of drugs.
The report contains the following four chapters:
Chapter 1: Global Pharmaceutical Market
Chapter 2: Solutions to Challenges
Chapter 3: Global Players
Chapter 4: Overview of Industry Trends
You may follow my blog: biostrategyanalytics.wordpress.com for further posts related to financial and strategic issues in the Pharmaceutical / Biotechnology sector.
For any questions or recommendations do not hesitate to contact me.
The document summarizes the global pharmaceutical industry, its history and competitive environment. It describes how the industry has evolved from the 1950s with new drug development and increased regulation. Barriers to entry into the industry are high and increasing due to lengthy development times and large R&D costs. The future of the industry is analyzed as facing continued pressure from generics, healthcare cost controls and industry consolidation into fewer large global companies focused on specific drug franchises.
This research service provides an in-depth analysis of the global pharmaceutical contract manufacturing market with particular focus on the finished dose formulations such as solid, liquid and semi-solid, and injectable dose formulations. Segment analysis, trends and revenue forecast for the global, U.S. and European regions have been provided in detail. Strategic recommendations for the success of market participants have also been discussed.
This document analyzes changes in the global pharmaceutical industry using the PESTEL framework. It discusses factors like increased political and regulatory hurdles, economic growth opportunities in biologics, social emphasis on health and direct-to-consumer advertising, technological focus on R&D and the long drug development pipeline, environmental risks of off-label promotion and lack of trust in companies, and the various legal bodies governing the industry. The key challenges identified are the long time required for new drug development, increased competition from companies in other regions, and damage to supply from companies prioritizing profits over safety. The conclusion calls for a faster drug development model to better meet medical needs and compete in the industry.
Business Plan- TLG Resources International LLCnroopraj24
This document provides an overview of T.L.G. Resources International's business plan. T.L.G. facilitates the procurement of Active Pharmaceutical Ingredients for pharmaceutical companies in the United States. It aims to become a leading supply chain enabler for sourcing internationally produced APIs. The business plan outlines T.L.G.'s services, the growing US pharmaceutical market, trends in the API supply chain industry, potential customers in the therapeutic drug categories with the largest market share, and projected strong financial performance over the first three years of operations.
Canada and Drug Costs (Pharmacare)| How to reform Drug Policypaul young cpa, cga
This document provides an overview of national pharmacare in Canada. It discusses what pharmacare is, reasons for high drug costs, comparisons to other countries' systems, and issues with implementing a national pharmacare program in Canada. Key points include that drug costs in Canada are among the highest in the world, patent laws and lack of competition contribute to high prices, and no government has successfully implemented a universal pharmacare program due to the significant costs involved.
The document analyzes the global pharmaceutical industry, identifying the United States and France as the largest markets. It outlines three key success factors for companies in the industry: having products in fast-growing therapeutic classes like oncology and diabetes; involvement in emerging biotechnology; and managing patent expirations. The document then evaluates Merck & Co. and Sanofi based on these three success factors.
Introduction to the pharmaceutical market and practiceWayne Wei
As a lecturer for "Basic Principles of Drug Discovery and Development" for Department of Life Sciences, National Central of University for two years.
In charge of "Introduction to the pharmaceutical market and practice".
This document provides an overview and analysis of financialization in the pharmaceutical industry, using Pfizer's attempted takeover of AstraZeneca as a case study. It finds that the erosion of the blockbuster drug model due to patent expirations, increasing costs, and regulatory pressures has reduced profitability and led pharmaceutical companies to pursue mergers and acquisitions to meet shareholder demands for returns. While M&As provide short-term growth, they may undermine long-term R&D productivity and threaten high-skilled jobs in the UK, as demonstrated by the Pfizer-AstraZeneca deal. The UK government has an obligation to consider the impact on domestic employment.
Pharma Uptoday Monthly Magazine Volume 14 Issue May 2015Sathish Vemula
This issue of Pharma Uptoday magazine covers the following topics:
1. New regulations for ozone systems used to disinfect pharmaceutical water under the Biocidal Products Regulation. Major manufacturers are working to get ozone approved as an active ingredient and register generation systems.
2. An overview of API manufacturing sites for the European market based on data in the EudraGMDP database, which shows the majority are located in India, China, and within the EEA. However, the data is not fully complete.
3. Plans by the FDA to change their facility inspection approach to provide both compliance assessments and recognize excellence in quality management systems. This could impact inspection frequency and post-approval flexibility.
2019 Election| National Pharmacare (Drugs) - Canada and the Provinces - July ...paul young cpa, cga
The document discusses issues around implementing a national pharmacare program in Canada. It notes that while some groups like National Pharmacists support helping the 10% of Canadians without drug coverage, a universal program could be very expensive to implement according to the Parliamentary Budget Officer. The document also points out that Ontario's drug program has faced issues of fraud and overspending according to the Ontario Auditor General, suggesting the government needs to address costs and oversight before expanding a national program.
This document provides a summary of the Oncology Drug Report 2014, which is described as the world's largest active resource for decision making in oncology. Some key details include:
- It covers 931 active cancer drug developers across 33 countries, along with profiles of 2237 active drugs in development, 37 cancer indications under pipeline analysis, and 523 clinical and 360 preclinical and discovery companies.
- The report is organized across 6 sections and provides comprehensive intelligence on the global oncology drug development landscape, including clinical trials, targets, mechanisms of action, deals and partnerships for individual drugs and companies.
- It aims to help businesses, scientists, investors and clinicians make better decisions by bringing extensive data together in one place
The pharmaceutical industry is shifting away from the traditional blockbuster drug model towards new business models. Long term strategies include adopting an integrated model that bundles drugs, healthcare services, and medical devices. Companies are also focusing on personalized drugs, disease management, and partnerships with biotech firms. Short term strategies involve semi-blockbuster portfolios, pre- and post-patent competition, and network-based research models relying more on outsourcing.
There has been an increase in R&D spending but a decline in research productivity, potentially leaving drug developers with insufficient pipelines. Mergers and acquisitions have aimed to strengthen pipelines and gain scale but larger companies now focus on blockbuster drugs. Licensing has become a major source of new products for large pharmaceutical companies and deals are occurring earlier in development stages.
This document provides a business plan for a new pharmaceutical company called NEWTech Advant. The plan includes a situation analysis of the pharmaceutical market, noting trends like an aging population and increased regulation. It outlines NEWTech Advant's goals of improving existing drugs and discovering new ones. The marketing strategy discusses targeting physicians and patients aged 45+, and increasing market share through advertising. Financial objectives include achieving profitability in three years. The plan also analyzes strengths, weaknesses, opportunities and threats for the new company.
The document defines and provides examples for several vocabulary words:
Oppression is the cruel and unfair treatment of people, especially by not giving them the same freedom and rights as others. Philanthropy is the practice of helping the poor and those in need, especially by giving money. Khakis refer to a strong greenish or yellowish brown cloth, used especially for making military uniforms. A poll is the process of voting at an election and counting the votes. Saliva is the liquid produced in your mouth that helps swallow food. A heyday refers to a time when somebody or something had most power or success and popularity. A caricature is a funny drawing that exaggerates some features of a person. Nirvana describes
Este documento proporciona información sobre una estudiante llamada Doriannys J. Manzaba C. con la identificación V-26082630 que está tomando el curso de Metodología de la Investigación II en la ciudad de Porlamar en diciembre de 2016.
Pharmaceutical Industry Environmental Analysis (Sanofi, Merck & Co.)Steven Sabo
The document is a letter of transmittal from a team of students to their professors submitting a report analyzing the global pharmaceutical companies Merck & Co. and Sanofi. The team's analysis identified three key success factors for companies in the industry and concluded that based on these factors, Sanofi is currently in a better position than Merck & Co. to succeed. The letter requests feedback from the professors and offers to further discuss the report and its analyses and recommendations.
The National Association of Pharmaceutical Manufacturers (NAPM) was established in 1977 as A Section 21 Trade Association which. It is a voluntary, non-profit organisation consisting of South African and Generics based Pharmaceutical manufacturers and distributors. The NAPM has a diverse membership comprising of 18 companies. Part of the NAPM’s function is to ensure that the sector plays a constructive role in our country’s economic growth, development and transformation and thereby create an environment in which the sector can thrive, expand, be competitive and enhance access of medicines to all of our country’s citizens.
Global Pharmaceutical Contract Manufacturing Resource Pack 2011Veronica Araujo
This document provides an overview of the global pharmaceutical contract manufacturing industry. It discusses key reasons why pharmaceutical companies outsource manufacturing, including lack of internal capacity, expertise, and the potential for cost savings. The most commonly outsourced areas of production are finished medicines. Emerging markets like India, China, and others offer lower costs and are attractive outsourcing destinations. However, outsourcing also presents challenges such as language/cultural barriers, meeting regulatory/quality requirements, and managing distant relationships. Overall, cost savings remain the top motivation for the 60% of pharmaceutical and biopharmaceutical manufacturing that is outsourced globally.
NAPM is a Section 21 Trade Association which was established in 1977. It is a voluntary, non-profit organisation consisting of South African and Generics based Pharmaceutical manufacturers and distributors. NAPM has a diverse membership comprising of 24 companies. Some of the NAPM’s function is to ensure that the sector plays a constructive role in our country’s economic growth, development and transformation and thereby create an environment in which the sector can thrive, expand, be competitive and enhance access of medicines to all of our country’s citizens.
What is the "Drugs (Prices Control) Order (DPCO)" ? The Drugs Prices Control Order, 1995 is an order issued by the Government of India under Sec. 3 of Essential Commodities Act, 1955 to regulate the prices of drugs.
The report contains the following four chapters:
Chapter 1: Global Pharmaceutical Market
Chapter 2: Solutions to Challenges
Chapter 3: Global Players
Chapter 4: Overview of Industry Trends
You may follow my blog: biostrategyanalytics.wordpress.com for further posts related to financial and strategic issues in the Pharmaceutical / Biotechnology sector.
For any questions or recommendations do not hesitate to contact me.
The document summarizes the global pharmaceutical industry, its history and competitive environment. It describes how the industry has evolved from the 1950s with new drug development and increased regulation. Barriers to entry into the industry are high and increasing due to lengthy development times and large R&D costs. The future of the industry is analyzed as facing continued pressure from generics, healthcare cost controls and industry consolidation into fewer large global companies focused on specific drug franchises.
This research service provides an in-depth analysis of the global pharmaceutical contract manufacturing market with particular focus on the finished dose formulations such as solid, liquid and semi-solid, and injectable dose formulations. Segment analysis, trends and revenue forecast for the global, U.S. and European regions have been provided in detail. Strategic recommendations for the success of market participants have also been discussed.
This document analyzes changes in the global pharmaceutical industry using the PESTEL framework. It discusses factors like increased political and regulatory hurdles, economic growth opportunities in biologics, social emphasis on health and direct-to-consumer advertising, technological focus on R&D and the long drug development pipeline, environmental risks of off-label promotion and lack of trust in companies, and the various legal bodies governing the industry. The key challenges identified are the long time required for new drug development, increased competition from companies in other regions, and damage to supply from companies prioritizing profits over safety. The conclusion calls for a faster drug development model to better meet medical needs and compete in the industry.
Business Plan- TLG Resources International LLCnroopraj24
This document provides an overview of T.L.G. Resources International's business plan. T.L.G. facilitates the procurement of Active Pharmaceutical Ingredients for pharmaceutical companies in the United States. It aims to become a leading supply chain enabler for sourcing internationally produced APIs. The business plan outlines T.L.G.'s services, the growing US pharmaceutical market, trends in the API supply chain industry, potential customers in the therapeutic drug categories with the largest market share, and projected strong financial performance over the first three years of operations.
Canada and Drug Costs (Pharmacare)| How to reform Drug Policypaul young cpa, cga
This document provides an overview of national pharmacare in Canada. It discusses what pharmacare is, reasons for high drug costs, comparisons to other countries' systems, and issues with implementing a national pharmacare program in Canada. Key points include that drug costs in Canada are among the highest in the world, patent laws and lack of competition contribute to high prices, and no government has successfully implemented a universal pharmacare program due to the significant costs involved.
The document analyzes the global pharmaceutical industry, identifying the United States and France as the largest markets. It outlines three key success factors for companies in the industry: having products in fast-growing therapeutic classes like oncology and diabetes; involvement in emerging biotechnology; and managing patent expirations. The document then evaluates Merck & Co. and Sanofi based on these three success factors.
Introduction to the pharmaceutical market and practiceWayne Wei
As a lecturer for "Basic Principles of Drug Discovery and Development" for Department of Life Sciences, National Central of University for two years.
In charge of "Introduction to the pharmaceutical market and practice".
This document provides an overview and analysis of financialization in the pharmaceutical industry, using Pfizer's attempted takeover of AstraZeneca as a case study. It finds that the erosion of the blockbuster drug model due to patent expirations, increasing costs, and regulatory pressures has reduced profitability and led pharmaceutical companies to pursue mergers and acquisitions to meet shareholder demands for returns. While M&As provide short-term growth, they may undermine long-term R&D productivity and threaten high-skilled jobs in the UK, as demonstrated by the Pfizer-AstraZeneca deal. The UK government has an obligation to consider the impact on domestic employment.
Pharma Uptoday Monthly Magazine Volume 14 Issue May 2015Sathish Vemula
This issue of Pharma Uptoday magazine covers the following topics:
1. New regulations for ozone systems used to disinfect pharmaceutical water under the Biocidal Products Regulation. Major manufacturers are working to get ozone approved as an active ingredient and register generation systems.
2. An overview of API manufacturing sites for the European market based on data in the EudraGMDP database, which shows the majority are located in India, China, and within the EEA. However, the data is not fully complete.
3. Plans by the FDA to change their facility inspection approach to provide both compliance assessments and recognize excellence in quality management systems. This could impact inspection frequency and post-approval flexibility.
2019 Election| National Pharmacare (Drugs) - Canada and the Provinces - July ...paul young cpa, cga
The document discusses issues around implementing a national pharmacare program in Canada. It notes that while some groups like National Pharmacists support helping the 10% of Canadians without drug coverage, a universal program could be very expensive to implement according to the Parliamentary Budget Officer. The document also points out that Ontario's drug program has faced issues of fraud and overspending according to the Ontario Auditor General, suggesting the government needs to address costs and oversight before expanding a national program.
This document provides a summary of the Oncology Drug Report 2014, which is described as the world's largest active resource for decision making in oncology. Some key details include:
- It covers 931 active cancer drug developers across 33 countries, along with profiles of 2237 active drugs in development, 37 cancer indications under pipeline analysis, and 523 clinical and 360 preclinical and discovery companies.
- The report is organized across 6 sections and provides comprehensive intelligence on the global oncology drug development landscape, including clinical trials, targets, mechanisms of action, deals and partnerships for individual drugs and companies.
- It aims to help businesses, scientists, investors and clinicians make better decisions by bringing extensive data together in one place
The pharmaceutical industry is shifting away from the traditional blockbuster drug model towards new business models. Long term strategies include adopting an integrated model that bundles drugs, healthcare services, and medical devices. Companies are also focusing on personalized drugs, disease management, and partnerships with biotech firms. Short term strategies involve semi-blockbuster portfolios, pre- and post-patent competition, and network-based research models relying more on outsourcing.
There has been an increase in R&D spending but a decline in research productivity, potentially leaving drug developers with insufficient pipelines. Mergers and acquisitions have aimed to strengthen pipelines and gain scale but larger companies now focus on blockbuster drugs. Licensing has become a major source of new products for large pharmaceutical companies and deals are occurring earlier in development stages.
This document provides a business plan for a new pharmaceutical company called NEWTech Advant. The plan includes a situation analysis of the pharmaceutical market, noting trends like an aging population and increased regulation. It outlines NEWTech Advant's goals of improving existing drugs and discovering new ones. The marketing strategy discusses targeting physicians and patients aged 45+, and increasing market share through advertising. Financial objectives include achieving profitability in three years. The plan also analyzes strengths, weaknesses, opportunities and threats for the new company.
The document defines and provides examples for several vocabulary words:
Oppression is the cruel and unfair treatment of people, especially by not giving them the same freedom and rights as others. Philanthropy is the practice of helping the poor and those in need, especially by giving money. Khakis refer to a strong greenish or yellowish brown cloth, used especially for making military uniforms. A poll is the process of voting at an election and counting the votes. Saliva is the liquid produced in your mouth that helps swallow food. A heyday refers to a time when somebody or something had most power or success and popularity. A caricature is a funny drawing that exaggerates some features of a person. Nirvana describes
Este documento proporciona información sobre una estudiante llamada Doriannys J. Manzaba C. con la identificación V-26082630 que está tomando el curso de Metodología de la Investigación II en la ciudad de Porlamar en diciembre de 2016.
La Estación Espacial Internacional es una estación espacial permanentemente tripulada en órbita terrestre bajo administración internacional. Europa participa a través de la Agencia Espacial Europea, que decidió formalmente su participación en 1995. La estación mide 109 metros de largo, 88 metros de ancho y 420 toneladas, y puede albergar hasta 6 astronautas con un volumen habitable de 916 metros cúbicos, alimentada por paneles solares de 84 kW.
El documento presenta una revisión del estado del arte de la deontología docente. Señala que una educación ética requiere cambios sustantivos en la formación de los docentes para sustraerla de su anacronismo e inercia. Una educación para la formación de ciudadanos éticos debe dar oportunidades de apertura, desilenciamiento y enfrentamiento con las contradicciones, en discrepancia y convergencia con los otros.
El Paso County Public Health (EPCPH) continued collaborating with community partners in 2015 to provide public health services and programs. EPCPH investigated the county's first measles case in over 20 years and partnered with local agencies to prevent its spread. EPCPH also launched new programs like Community Resource Navigators to connect people to services. Moving forward, EPCPH plans to expand substance abuse, suicide prevention, and behavioral health services while conducting a community health assessment and improvement plan.
This document provides instructions for writing a bibliography in the Harvard referencing style, including examples of how to reference different source types such as books, magazines, newspapers, and websites. A bibliography is a list of all references cited in a piece of work. It should be arranged alphabetically by author surname and includes full details of each source to allow them to be identified and located.
- The document is about a social life activity where students are split into groups and listen to a story. They must then stand if they have a picture related to what was heard.
- It also provides vocabulary words and explanations of stress patterns in two-syllable words. Examples are given.
- The last part of the document is song lyrics with a discussion of the meaning and answers multiple choice questions about the lyrics.
This document asks where various pieces of furniture are located in a room, including a table, chairs, plant, bed, chest of drawers, bookcase, chair, TV-set, and lamp.
Construction of phylogenetic tree from multiple gene trees using principal co...IAEME Publication
This document describes a method for constructing a phylogenetic tree from multiple gene trees using principal component analysis. Multiple gene trees are generated from different protein sequences from various organisms. Distance matrices are calculated for each gene tree and combined into a single data matrix. Principal component analysis is performed on the data matrix to extract the first principal component, which represents the consensus distance vector combining information from all gene trees. A phylogenetic tree is then generated from the consensus distance vector using UPGMA, providing a species tree that integrates information from multiple genes. The method is demonstrated on protein sequence data from primates and placental mammals.
UD 04 - Roma y la expansión del Arte Clásico. La Iberia de las colonizaciones.Inmaculada Sosa Borrego
Los romanos adoptaron el arte clásico griego pero lo adaptaron a sus propias necesidades, expandiendo su influencia por todo el Imperio. Conquistaron regiones como Grecia y la Península Ibérica, imponiendo su cultura e influyendo en el arte local. El arte romano se caracterizó por ser más funcional y realista, aunque conservó la belleza del arte griego.
El documento describe brevemente la ingeniería romana y algunos de sus logros. La ingeniería romana se centraba en la construcción de obras públicas permanentes como acueductos, carreteras y puentes utilizando esclavos. Algunos de sus mayores triunfos incluyen el Coliseo y la Vía Apia. También desarrollaron técnicas avanzadas como el uso de múltiples niveles de arcos para construir acueductos a través de cañadas y la invención del ariete para atacar murallas.
Este documento presenta información sobre varios ejemplos de arquitectura precolombina en América, incluyendo el Templo de Kukulkán en Chichén Itzá, la Pirámide del Sol y la Pirámide de la Luna en Teotihuacán, la Pirámide de Tikal en Guatemala, Machu Picchu, La Gran Pirámide de la Danta, los ushnus incas, las canchas aztecas de juego de pelota, los acllahuasis en Cuzco y el Montículo 1 de Bandurria en Perú.
The document outlines ideas for "How To" videos, including topics like how to be famous, how to rap, how to bake a cake, how to build a fire, how to style your hair, how to dress like a celebrity, how to survive college, how to enroll at university, and how to be a YouTuber. For each idea, it provides details on the approach, locations, and shots that could be used. The majority of the ideas involve filming in different locations to demonstrate the topic in a comedic, factual, or tutorial style.
This document discusses the use of possessives in English. It explains that:
1) Possessive 's is usually used after names of people, animals, and organizations to show possession, like Mark's jacket or the dog's lead.
2) An "of" phrase is usually used with other nouns, like the name of the street.
3) If a name ends in -s, the possessive can be formed with just an apostrophe or 's, like Chris' advice.
4) Possessives are formed differently for regular and irregular plurals.
This document provides information and examples about using the past simple tense in English. It includes:
1) Forms of regular and irregular verbs in the past simple (e.g. worked, was);
2) Questions in the past simple using auxiliary verbs (e.g. did, was);
3) Spelling rules for forming regular past simple verbs;
4) Pronunciation rules for regular past simple verbs.
The document analyzes and dispels five common myths about the drug delivery industry. It argues that far from being a declining sector, drug delivery has delivered steady product approvals over the past decade and continues to be an important source of new products. It also contends that the drug delivery market is growing, drug delivery business models can be sustainable, product line extensions using drug delivery technologies are effective strategies, and drug delivery companies offer diverse technologies, not just similar controlled release solutions.
Writekraft Research and Publications LLP was initially formed, informally, in 2006 by a group of scholars to help fellow students. Gradually, with several dissertations, thesis and assignments receiving acclaim and a good grade, Writekraft was officially founded in 2011 . Since its establishment, Writekraft Research & Publications LLP is Guiding and Mentoring PhD Scholars.
Our Mission
“To provide breakthrough research works to our clients through Perseverant efforts towards creativity and innovation”.
Vision
Writekraft endeavours to be the leading global research and publications company that will fulfil all research needs of our clients. We will achieve this vision through:
Analyzing every customer’s aims, objectives and purpose of research
Using advanced and latest tools and technique of research and analysis
Coordinating and including their own ideas and knowledge
Providing the desired inferences and results of the research
In the past decade, we have successfully assisted students from various universities in India and globally. We at Writekraft Research & Publications LLP head office in Kanpur, India are most trusted and professional Research, Writing, Guidance and Publication Service Provider for PhD. Our services meet all your PhD Admissions, Thesis Preparation and Research Paper Publication needs with highest regards for the quality you prefer.
Our Achievements
NATIONAL AWARD FOR BEST RESEARCH PROJECT (By Hon. President APJ Abdul Kalam)
GOLD MEDAL FOR RESEARCH ON DISABILITY (By Disabled’s Club of India)
NOMINATED FOR BEST MSME AWARDS 2017
5 STAR RATING ON GOOGLE
We have PhD experts from reputed institutions/ organizations like Indian Institute of Technology (IIT), Indian Institute of Management (IIM) and many more apex education institutions in India. Our works are tailored and drafted as per your requirements and are totally unique.
From past years our core advisory members, research team assisted research scholars from various universities from all corners of world.
This document provides an overview of marketing strategies used by pharmaceutical companies in India. It begins with background on the large size of the global pharmaceutical industry and growth of the Indian pharmaceutical industry. The marketing challenges described include increased competition, lack of customer knowledge, and ineffective customer acquisition, development and retention strategies. The document then outlines two common business models - the super core model focusing on a small number of blockbuster drugs, and the core model marketing a larger number of drugs across therapeutic areas. The goals of the proposed research are to identify factors affecting competitiveness, investigate effective customer strategies, and provide alternative strategies to improve competitiveness.
Writekraft Research and Publications LLP was initially formed, informally, in 2006 by a group of scholars to help fellow students. Gradually, with several dissertations, thesis and assignments receiving acclaim and a good grade, Writekraft was officially founded in 2011 . Since its establishment, Writekraft Research & Publications LLP is Guiding and Mentoring PhD Scholars.
Our Mission
“To provide breakthrough research works to our clients through Perseverant efforts towards creativity and innovation”.
Vision
Writekraft endeavours to be the leading global research and publications company that will fulfil all research needs of our clients. We will achieve this vision through:
• Analyzing every customer’s aims, objectives and purpose of research
• Using advanced and latest tools and technique of research and analysis
• Coordinating and including their own ideas and knowledge
• Providing the desired inferences and results of the research
In the past decade, we have successfully assisted students from various universities in India and globally. We at Writekraft Research & Publications LLP head office in Kanpur, India are most trusted and professional Research, Writing, Guidance and Publication Service Provider for PhD. Our services meet all your PhD Admissions, Thesis Preparation and Research Paper Publication needs with highest regards for the quality you prefer.
Writekraft Research and Publications LLP was initially formed, informally, in 2006 by a group of scholars to help fellow students. Gradually, with several dissertations, thesis and assignments receiving acclaim and a good grade, Writekraft was officially founded in 2011 . Since its establishment, Writekraft Research & Publications LLP is Guiding and Mentoring PhD Scholars.
Writekraft Research & Publications LLP
(Regd. No. AAI-1261)
Mobile: 7753818181, 9838033084
Email: info@writekraft.com
Web: www.writekraft.com
Research Paper Writing
Writekraft Research and Publications LLP was initially formed, informally, in 2006 by a group of scholars to help fellow students. Gradually, with several dissertations, thesis and assignments receiving acclaim and a good grade, Writekraft was officially founded in 2011 . Since its establishment, Writekraft Research & Publications LLP is Guiding and Mentoring PhD Scholars.
Our Mission
“To provide breakthrough research works to our clients through Perseverant efforts towards creativity and innovation”.
Vision
Writekraft endeavours to be the leading global research and publications company that will fulfil all research needs of our clients. We will achieve this vision through:
Analyzing every customer’s aims, objectives and purpose of research
Using advanced and latest tools and technique of research and analysis
Coordinating and including their own ideas and knowledge
Providing the desired inferences and results of the research
In the past decade, we have successfully assisted students from various universities in India and globally. We at Writekraft Research & Publications LLP head office in Kanpur, India are most trusted and professional Research, Writing, Guidance and Publication Service Provider for PhD. Our services meet all your PhD Admissions, Thesis Preparation and Research Paper Publication needs with highest regards for the quality you prefer.
Writekraft Research and Publications LLP was initially formed, informally, in 2006 by a group of scholars to help fellow students. Gradually, with several dissertations, thesis and assignments receiving acclaim and a good grade, Writekraft was officially founded in 2011 . Since its establishment, Writekraft Research & Publications LLP is Guiding and Mentoring PhD Scholars.
The healthcare ecosystem is rapidly changing as it transitions to Pharma 3.0. In the past year, pharmaceutical companies have expanded their Pharma 3.0 initiatives by 78%, with nearly half of all initiatives launched in 2010 alone. However, pharmaceutical companies are still investing much less in Pharma 3.0 business model innovation than non-traditional players, who have invested an estimated $20 billion. The ecosystem has also grown more complex, as initiatives have expanded across more disease areas, technologies, and stages of care. The rapid rise of mobile health apps, especially smartphone apps, has been a major driver of new Pharma 3.0 initiatives. However, pharmaceutical investment in Pharma 3.0 remains far below what is needed
its not my personal work presentation but taken from lecture ppt from university of San Diego, california.
Its about the drug discovery process, its development and its commercialization.
The document discusses marketing strategies used by pharmaceutical companies. It notes that companies are shifting from acute therapies to focusing more on chronic therapies that require long-term treatment. This allows companies to build more stable customer bases. The document also outlines some of the challenges companies face, such as increased competition, high costs of research and development, and complex decision-making processes involving doctors, patients, and other stakeholders. It discusses two common business models - the "super core model" involving a small number of highly successful chronic drugs, and the "core model" involving marketing a larger number of acute drugs.
The document discusses marketing strategies used by pharmaceutical companies. It notes that companies are shifting from acute therapies to focusing more on chronic therapies. This represents a long-term strategy change as chronic therapies require doctors to prescribe the same drugs for longer periods. The document also outlines some of the challenges pharmaceutical companies face in marketing to different customers in the supply chain from doctors to patients. It discusses strategies around patents, research and development, and pursuing either a "super core" model focused on a small number of chronic drugs or a "core" model marketing more acute drugs.
PharmAsia Summit2013 report "In search of new growth models for Big Pharma in...Franck Le Deu
The pharmaceutical market in China continues to grow rapidly, projected to reach $1.9 trillion by 2020. Key drivers of growth include an aging population, rising rates of chronic diseases due to lifestyle changes, and improved healthcare access and insurance coverage. While China represents a major opportunity, multinational companies face challenges from increasing cost containment pressures, regulatory hurdles, and a recent anti-corruption probe. To succeed, companies will need new business models that address these realities.
Merck Paper Securities and Protfolio AnalysisJason Sandoy
Merck & Co. is a large pharmaceutical company that produces many drugs across different medical fields. The report recommends buying Merck stock based on its large drug pipeline, cost savings initiatives, and undervaluation relative to estimates. Merck allocates billions to research and development each year to develop new drugs and maintain a diverse portfolio to drive future growth. While some ratios show Merck lagging competitors, its growth rates exceed industry averages, and initiatives to reduce costs are expected to increase returns. Overall the report finds Merck positioned for continued growth and profitability.
Outsourcing in Drug Development: The Contract Research (Clinical Trial) MarketMarketResearch.com
The cost and time of developing and bringing a drug to market is over $1.3 billion and often takes as long as 15 years, if not longer. Because of this, major pharmaceutical marketers continue to outsource stages of development, and over the years Kalorama Information has observed this process. In past editions of our outsourcing market studies, we found that outsourcing moved from "should" to "must." for manufacturers. This trend has only continued in the past two years. Contract Research Organizations (CROs) and other entities can expect growing demand for their services.
The demand for new drugs remains unabated, but the cost and need to bring those drugs to market is ever-increasing and intensifying. A key cost driver is the large number of failures during the expensive clinical trial phases. Driven by pressures to reduce costs, companies are increasingly implementing outsourcing strategies to increase revenues through faster drug development. By decreasing their in-house facilities and staff, and outsourcing more of their R&D functions, pharmaceutical and biotechnology companies are reshaping the drug development services industry.
Kalorama Information's Outsourcing in Drug Development: The Contract Research (Clinical Trial) Market is the third edition of this study of the drivers for outsourcing drug development, the companies involved in this market and the opportunity for revenues.
This document summarizes a study that analyzed the financial performance of publicly listed pharmaceutical companies in Indonesia before and during the COVID-19 pandemic from Q4 2018 to Q1 2021. The study found that only the net profit margin ratio showed a significant difference between the two periods, with a positive effect. A multiple regression analysis found that several ratios (current ratio, cash ratio, total assets inventory, inventory turnover, debt to assets ratio, return on equity) collectively influenced stock prices. Individually, current ratio negatively affected stock prices, inventory turnover negatively affected stock prices, and return on equity positively affected stock prices. The study used financial ratio analysis and paired t-tests to evaluate differences in company performance and the impact of ratios on stock
Measuring the Relationship between Innovative Drugs and AE_2015Jonathan Bryan
This study used logistic regression to analyze the relationship between drug innovation classes and reported adverse events. It utilized a previous study's classification of 645 drugs from 1987-2011 into first-in-class, advanced-in-class, or addition-to-class based on FDA review designations. Adverse event data was obtained from FAERS reports from 2004-2014. The results found that total adverse events per drug followed a power law distribution, with most drugs having few events but some outliers with many. Logistic regression found a weak relationship between adverse events and innovation classes, except for more advanced-in-class drugs having higher lifetime adverse event totals. This highlights the need for more systematic drug outcome data to develop better models of drug
U.S. Specialty Injectable Generics Market Size, Share and Research Report, 20...Signitech
The U.S. specialty injectable generics market size was valued at USD 8.05 billion in 2016 and is expected to witness a lucrative CAGR of 14.9% over the forecast period. Increase in prevalence of target diseases, such as cancer, hepatitis C, multiple sclerosis, and others, has resulted in high demand for specialty generic drugs.
This document summarizes a research paper analyzing asymmetric information between governments and pharmaceutical companies in R&D for drugs targeting neglected infectious diseases. It outlines push and pull strategies used by governments to incentivize private sector R&D. Under push strategies like grants, moral hazard arises as firms may divert funds to more profitable projects. The paper uses a principal-agent model to show that firms are better off diverting funds under push strategies. It suggests pull strategies that reward success may better align incentives.
To recap the previous month's pharma highlights to members, Monthly magazine Volume 20 has been released with the following content.
News Uptoday
New Guidance
Audit Findings
- Pernix Receives Form 483 for cGMP Violations
- FDA Hits Pfizer Subsidiary With Second Form 483 in Five Years
- Galena Hit With 10-Item Form 483 Over Unresolved Issues
Warning Letters
- Warning letter: Unimark Remedies Ltd., Mumbai, India
- Warning letter: SSM Health Care St. Louis DBA SSM St. Clare Health Center
Health Canada Non Compliance Report
- Non Compliance Report: Unilever Canada Inc.
EMA Non-Compliance Report
- GlaxoSmithKline (Tianjin) Company Limited (Teda), China
- CARGILL FRANCE
Regulations of the Month
- Sec. 211.42 Design and construction features (c)(5) to (c)(10)
- Sec. 211.44 Lighting
This document provides a summary and schedule for presentations at the 57th Annual Meeting of the American Society of Hematology (ASH) being held from December 5-8, 2015 in Orlando, FL. Key highlights mentioned include presentations on venetoclax for CLL, KTE-C19 CAR-T therapy for NHL, Zydelig for CLL, Ninlaro for multiple myeloma, Keytruda for CLL, and Imbruvica for CLL. The document also includes full schedules of presentations for each day of the conference divided by topic.
This document discusses the growing field of anticancer immunotherapy and summarizes key points:
1) Immunotherapy harnesses the immune system to fight cancer and represents a relatively new approach, with the number of immunotherapies in development rising from 1 in 1995 to over 170 currently.
2) Three immunotherapies have been successfully launched, including ipilimumab, nivolumab, and pembrolizumab, which target checkpoints like CTLA-4 and PD-1 to activate antitumor immune responses.
3) Many more immunotherapies are in clinical trials, especially those targeting PD-1 and PD-L1, and CAR T-cell therapies show promise in hematological
European Cancer Congress 2015 Conference InsightYujia Sun
- Phase II data from studies of Roche's PD-L1 inhibitor atezolizumab showed promising efficacy in NSCLC and bladder cancer, positioning it as a potential front-runner for first-line NSCLC treatment ahead of rival drugs. In bladder cancer, atezolizumab could become the first approved PD-1/PD-L1 immunotherapy.
- Updated results from the POPLAR study directly compared atezolizumab to docetaxel in pre-treated NSCLC, showing a nearly 3 month improvement in overall survival with fewer side effects for atezolizumab. Efficacy was correlated with PD-L1 tumor expression.
- Positive data from POPLAR support Roche's planned early 2016 FDA
1) The document analyzes how the number of countries included in clinical trials affects enrollment rates for various diseases.
2) It finds that for most diseases, trials that took place in 10-14 countries had the highest rates of meeting enrollment targets. NSCLC was an exception, doing better with 5-9 countries.
3) As the number of countries in Alzheimer's and NSCLC trials increased, average enrollment and patients/month increased, but patients/month/site generally decreased, suggesting these trials relied on larger numbers of sites.
This document summarizes the development of novel biologics for uncontrolled asthma. 19 clinical programs have targeted the IL-5, IL-4, and IL-13 pathways over 18 years. Approximately half were discontinued, with challenges for IL-4 and IL-13 antagonists. Programs still active include mepolizumab, reslizumab, benralizumab, tralokinumab, lebrikizumab, and dupilumab targeting IL-5 and Th2 cytokines. Inclusion criteria focus on eosinophilic and uncontrolled asthma. Biomarkers like eosinophil levels are used. Primary endpoints for pivotal trials are exacerbations and steroid use.
Is the pipeline for obesity therapies set to expand with waistlinesYujia Sun
The document discusses obesity pharmacotherapies that are currently in development. It finds that while there are 92 preclinical compounds and 18 in Phase I trials, attrition is high, with drug counts decreasing by 80% between preclinical and Phase I, and 33% between Phase I and Phase II. Currently, there are two Phase III compounds and one registered but not yet launched drug. The document analyzes the mechanisms of action and targets of current development programs and finds a focus on peripheral rather than central targets, including GLP-1, glucagon, and metabolic regulatory enzymes and proteins.